Salud financiera de hoja de balance de SymBio Pharmaceuticals

Salud financiera controles de criterios 6/6

SymBio Pharmaceuticals tiene un patrimonio de los accionistas total de ¥5.2B y una deuda total de ¥0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son ¥6.1B y ¥910.3M respectivamente.

Información clave

Ratio deuda-patrimonio

JP¥0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	JP¥5.13b
Patrimonio	JP¥5.16b
Total pasivo	JP¥910.31m
Activos totales	JP¥6.07b

Actualizaciones recientes sobre salud financiera

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09

Recent updates

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Aug 06

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

Jun 11

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Dec 18

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (¥6.0B) de 4582 superan a sus pasivos a corto plazo (¥906.0M).

Pasivo a largo plazo: Los activos a corto plazo de 4582 (¥6.0B) superan a sus pasivos a largo plazo (¥4.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 4582 está libre de deudas.

Reducción de la deuda: 4582 no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 4582 tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 4582 tiene suficiente cash runway para más de 3 años si el flujo de caja libre sigue creciendo a tasas históricas de 34.4% cada año

Salud financiera de hoja de balance de SymBio Pharmaceuticals

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals ADR - Sponsored to Be Deleted from OTC Equity

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Recent updates

Third quarter 2024 earnings released: JP¥28.45 loss per share (vs JP¥17.83 loss in 3Q 2023)

SymBio Pharmaceuticals Limited to Report Q3, 2024 Results on Oct 31, 2024

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Second quarter 2024 earnings released: JP¥16.75 loss per share (vs JP¥2.09 loss in 2Q 2023)

SymBio Pharmaceuticals Limited to Report Q2, 2024 Results on Aug 01, 2024

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

New major risk - Share price stability

First quarter 2024 earnings released: JP¥18.02 loss per share (vs JP¥0.10 profit in 1Q 2023)

Full year 2023 earnings released: JP¥49.17 loss per share (vs JP¥30.20 profit in FY 2022)

SymBio Pharmaceuticals Limited announced that it has received ¥256.5 million in funding from Evolution Capital Management LLC

Full year 2023 earnings released

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024

SymBio Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 08, 2024

Third quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 26%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 23, 2023

SymBio Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Feb 09, 2023

Third quarter 2022 earnings released: EPS: JP¥11.32 (vs JP¥13.83 in 3Q 2021)

Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022

SymBio Pharmaceuticals Limited to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: JP¥24.36 (vs JP¥0.11 in 2Q 2021)

Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022

SymBio Pharmaceuticals ADR - Sponsored to Be Deleted from OTC Equity

SymBio Pharmaceuticals Limited to Report Q2, 2022 Results on Aug 04, 2022

SymBio Pharmaceuticals Limited announced that it has received ¥675.76 million in funding from CVI Investments, Inc.

Investor sentiment improved over the past week

SymBio Pharmaceuticals Limited announced that it expects to receive ¥675.76 million in funding from CVI Investments, Inc.

First quarter 2022 earnings released: EPS: JP¥4.25 (vs JP¥5.47 loss in 1Q 2021)

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Less than half of directors are independent

SymBio Pharmaceuticals Limited to Report Q1, 2022 Results on May 11, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Third quarter 2021 earnings released: EPS JP¥13.79 (vs JP¥23.01 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥0.10 (vs JP¥27.30 loss in 2Q 2020)

First quarter 2021 earnings released

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

SymBio Pharmaceuticals Limited to Report Q1, 2021 Results on May 13, 2021

New 90-day high: JP¥1,380

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

New 90-day high: JP¥895

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2021

New 90-day low: JP¥337

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Third quarter 2020 earnings released: JP¥23.01 loss per share

New 90-day low: JP¥379

Symbio Pharmaceuticals Limited Receives Approval of TREAKISYM Ready-To-Dilute ('Rtd') Formulation, with Launch Expected in January 2021

New 90-day low - JP¥409

Earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera